Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Zealand Pharma shared positive trial results for its dasiglucagon – 99% of participants recovered from hypo within 15 minutes of treatment
The latest on Dexcom’s work with Verily to make a more simple and accessible CGM; also, the “Pro Q” professional CGM and insulin dosing advice for people on multiple...
Xeris’ Glucagon Rescue Pen, designed as an auto-injector, features a ready-to-use liquid glucagon – a safer and more convenient treatment option for severe hypoglycemia
Results from the CREDENCE trial suggest that Invokana’s kidney benefits exist on top of blood pressure lowering medications (standard of care)
Insightful diabetes leaders discuss high-potential areas ranging from SGLT-2s in type 1 diabetes, personalized treatment plans, and the do-it-yourself Loop app
Sanofi covers all insulins under this program, including Toujeo, Lantus, Admelog, Apidra.
A new study will investigate whether SGLT-2 inhibitor Farxiga can delay the progression of heart failure in people with and without type 2 diabetes
Surprising study findings from a look at refrigerator temperatures and the risk posed to insulin quality; plus, a guide to safe insulin storage and Med Angel’s very cool...
CVS now offers same-day prescription home delivery from 6,000 pharmacies across the United States for a delivery charge of $7.99.
A study is enrolling over 100 people with type 2 between the ages of 10 and 18 years, examining Jardiance and Tradjenta
The study aims to enroll about 1,800 adults with type 2 diabetes at increased risk of heart disease
The EMA approved Zynquista (sotagliflozin), an SGLT-1/2 dual inhibitor, for adults with a BMI above 27
The most promising therapies in the pipeline, accuracy data on the FreeStyle Libre 2, and more
For now, another SGLT-2 inhibitor pill already approved for people with type 2 diabetes is not approved for people with type 1 diabetes in the US. The drug was recently...
Farxiga’s heart health benefits were the same in people with and without diabetes, as well as across a spectrum of baseline A1C levels
A new premixed, liquid glucagon coming in October in a prefilled syringe and in 2020 as an auto-injector. The second stable glucagon approved this year
By Becky Milner A company called Intarcia has developed a GLP-1 mini-pump that is implanted under the skin to continuously provide medication for six months at a time –...
These new rules will save both consumers and health plan providers thousands of dollars a year through pre-deductible coverage of chronic condition treatments
New guidelines from ADA and EASD focus on GLP-1 agonists and SGLT-2 inhibitors to improve heart and kidney health
Xofluza was recently approved to treat the flu in higher-risk populations – people with diabetes or other chronic conditions, and people over age 65 – and to prevent...

Pages